

Date: 05/07/08

Pharmacy Announcement

Annual Review of Preferred Drug List (PDL) – June 26, 2008

The Pharmacy and Therapeutics (P&T) Committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy (DHCFP) will conduct an annual review of the Preferred Drug List (PDL) at their meeting scheduled for June 26, 2008. Drugs that will be considered for change and those drug classes without proposed changes are listed below. The meeting agenda and Drug Class Reviews for those classes to be considered for change will be posted to the First Health Services website prior to the meeting (at <https://medicaid.nv.gov> select "Meetings" from the "Pharmacy" menu).

Submission of clinical information or comments pertaining to any of the drug classes listed below must be received no later than May 28, 2008. Please send the material via e-mail to Jeff Monaghan, Pharm.D., Clinical Account Manager for First Health Services at jlmonaghan@cvty.com.

Drug classes with proposed changes have been determined based on the following criteria:

1. New drugs within the class since the last annual review.
2. Clinician's input and/or new compelling clinical evidence since the last annual review.
3. Classes the Committee has requested to be reviewed.
4. DHCFP recommendations based on changes in the National Medicaid Pooling Initiative (NMPI).

Drug Classes to be Considered for Change:

- Antidepressants: Other
- Antihistamines: 2nd Generation
- Cardiovascular: Antihyperlipidemics: Statins & Statin Combinations
- Cardiovascular: Antihyperlipidemics: Other
- Ophthalmic Glaucoma Agents
- Ophthalmic Quinolones
- Respiratory: Long Acting Beta Adrenergics
- Respiratory: Nasal Corticosteroids

Drug Classes without Proposed Changes:

- Analgesics: Long Acting Narcotics
- Antibiotics: Cephalosporins 2nd Generation
- Antibiotics: Cephalosporins 3rd Generation
- Antibiotics: Macrolides
- Antibiotics: Quinolones 2nd Generation
- Antibiotics: Quinolones 3rd Generation
- Anticoagulants: Injectable
- Antidepressants: SSRIs
- Antiemetics: Oral, 5-T3s
- Antifungals: Onychomycosis Agents
- Anti-Migraine Agents: Triptans
- Bone Ossification Agents: Bisphosphonates
- Cardiovascular: ACE Inhibitors & Diuretic Combinations
- Cardiovascular: Angiotensin II Receptor Blockers & Diuretic Combinations
- Cardiovascular: Beta Blockers
- Cardiovascular: Calcium Channel Blockers & Combinations
- Central Nervous System: ADHD/Stimulants
- Central Nervous System: Sedative Hypnotics
- Electrolyte Depleters
- Erythropoiesis Stimulating Proteins
- Gastrointestinal Agents: H2RAs
- Gastrointestinal Agents: PPIs
- Growth Hormone Agents
- Hepatitis C Agents
- Herpetic Antiviral Agents
- Immunomodulators: Injectable
- Immunomodulators: Topical
- Leukotriene Modifiers
- Multiple Sclerosis Agents
- Nasal Calcitonins
- Ophthalmic Antihistamines
- Otic Fluoroquinolones
- Respiratory: Inhaled Anticholinergic Agents
- Respiratory: Inhaled Corticosteroids/Nebs
- Respiratory: Short Acting Beta Adrenergic-Inhalers/Nebs
- Urinary Tract Antispasmodics

PA-050708-PDLRVW